Literature DB >> 15515588

Chemotherapy followed by half-body radiation therapy for canine lymphoma.

Laurel E Williams1, Jeffrey L Johnson, Marlene L Hauck, David M Ruslander, G Sylvester Price, Donald E Thrall.   

Abstract

A protocol of induction chemotherapy followed by half-body radiation therapy for treatment of lymphoma was used in 94 dogs. Seventy-three (78%) dogs achieved complete remission. Substage (P = .011) and phenotype (P = .015) were identified as predictors of complete remission rate. Of these, 52 dogs received half-body irradiation. Cranial and caudal halves received a total dose of 8.0 Gy, given in 2 fractions of 4.0 Gy on consecutive days with cobalt-60 photons and a 3-week interval between halves. Median 1st remission for these dogs was 311 days. Anemia was identified as the only predictor for length of 1st remission (P = .024). Toxicoses after half-body irradiation generally were mild and infrequent and included myelosuppression and gastrointestinal signs. Thirty-one dogs relapsed and 20 resumed treatment with induction followed by maintenance chemotherapy. Seventeen (85%) dogs achieved a 2nd complete remission. Median overall remission for all 52 dogs was 486 days. Results of this study suggest that half-body radiation therapy after induction chemotherapy is well tolerated and might increase remission duration compared with conventional protocols that use chemotherapy alone, but this increase might not be long enough to be clinically relevant or to justify application of the method described herein.

Entities:  

Mesh:

Year:  2004        PMID: 15515588     DOI: 10.1892/0891-6640(2004)18<703:cfbhrt>2.0.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  6 in total

1.  Oxidative stress in dogs with multicentric lymphoma: Effect of chemotherapy on oxidative and antioxidant biomarkers.

Authors:  Nathieli B Bottari; Thiago D Munhoz; Vanessa D Torbitz; Alexandre A Tonin; Letícia A Anai; Lívia M S Semolin; Paulo C Jark; Yãnaí S Bollick; Rafael N Moresco; Raqueli T França; Sonia T A Lopes; Lenita M Stefani; Mirela Tinucci-Costa; Aleksandro S Da Silva
Journal:  Redox Rep       Date:  2015-08-14       Impact factor: 4.412

Review 2.  Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?

Authors:  Kristy L Richards; Steven E Suter
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

3.  Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro.

Authors:  Jeffrey N Bryan; Senthil R Kumar; Fang Jia; Ethan R Balkin; Michael R Lewis
Journal:  Cell Biol Int       Date:  2013-12-09       Impact factor: 3.612

4.  Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model.

Authors:  M Lupu; R Storb
Journal:  Vet Comp Oncol       Date:  2007-03       Impact factor: 2.613

5.  Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma.

Authors:  E E Warry; J L Willcox; S E Suter
Journal:  J Vet Intern Med       Date:  2014-01-27       Impact factor: 3.333

6.  Prospective evaluation of the lymph node proteome in dogs with multicentric lymphoma supplemented with sulforaphane.

Authors:  Cyril Parachini-Winter; Shay Bracha; Stephen A Ramsey; Liping Yang; Emily Ho; Haley J Leeper; Kaitlin M Curran
Journal:  J Vet Intern Med       Date:  2020-09-14       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.